

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 5, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Paratek Pharmaceuticals, Inc.

File No. 1-36066 - CF#36081

Paratek Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibit 10.17 to a Form 10-K filed on April 2, 2015, as modified by the same contract refiled with fewer redactions as Exhibit 10.17 to a Form 10-K filed on March 6, 2018.

Based on representations by Paratek Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.17 to Form 10-K filed April 2, 2015	through April 1, 2021
Exhibit 10.17 to Form 10-K filed March 8, 2018	through April 1, 2021

For the Commission, by the Division of Corporation Finance, pursuant to Delegated Authority:

Brent J. Fields
Secretary